The global burden of acute ischemic stroke is rising, with cases expected to increase from seven million in 2025 to nearly 10 million by 2035. Demand for faster, more effective treatment is prompting expansion of thrombectomy, a stroke intervention traditionally used for large vessel occlusion (LVO) that is now being adopted more widely for medium vessel occlusions (MVO). Rapid growth in MVO treatment, evolving device preferences, and rising prices will combine to unlock new revenue opportunities in the thrombectomy market, according to GlobalData, a leading data and analytics company.

GlobalData’s latest Neurovascular Thrombectomy Devices market report contains detailed insights about stroke incidence and device trends, forecasting market growth from $1.2 billion in 2025 to $5.0 billion by 2035, with 87% of the 2035 market value attributed to aspiration catheters.

Ashley Clarke, Senior Medical Analyst at GlobalData, comments: “Major challenges persist in ensuring patients reach healthcare facilities quickly, receive diagnostics, and begin treatment within the narrow effective window. Strict eligibility criteria limit access to thrombectomy to those most likely to benefit. Since 40% of ischemic strokes are LVO while another 30% are MVO, expanding treatment to include even a portion of MVO patients will extend this life-saving option to more patients.”

In the US, intervention rates for LVO increased from 24% in 2020 to 29% in 2025, while MVO rates grew from 7% to 19%. These gains reflect improved diagnostics and clinician confidence in treating MVO. Comparable trends in other countries suggest MVO will become a much larger share of thrombectomy procedures globally moving forward.

Clarke continues: “Physicians prefer devices that enable simpler access, shorter procedure durations, and lower risk. The rising number of MVO interventions is driving changes in device design and selection, with aspiration catheters—particularly smaller-diameter models—gaining traction.”

In the US, the fraction of thrombectomy interventions using aspiration catheters has increased from about 46% in 2020 to 72% in 2025. Aspiration catheters are also often less than half the cost of stent retrievers, which supports adoption in regions with constrained reimbursement. Prices for aspiration catheters may increase with demand, supply chain constraints, and improvements in design and accessories. Manufacturers are exploring bundled offerings to add value and integrate complementary technologies. Though catheters remain more affordable, these trends suggest they could overtake stent retrievers in price.

Clarke concludes: “With the anticipated rises in patient demand, intervention rates, and prices, the neurovascular thrombectomy market is poised for significant growth. Regions with lower intervention rates represent both the greatest challenge and the greatest opportunity for investment and innovation. Manufacturers and providers who further contribute to improving intervention access stand to lead this evolving landscape.”